Evidence map›Paper›PMID 29545603›Full record

ArticleOncogene2018

Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.

Jingxiao Wang, Mingjie Dong, Zhong Xu, Xinhua Song, Shanshan Zhang, Yu Qiao, Li Che, John Gordan, Kaiwen Hu, Yan Liu and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 115 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Cellular Origins and Lineage Plasticity in Cancer.Cold Spring Harbor perspectives in medicine · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Jingxiao WangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Mingjie DongDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Zhong XuDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Xinhua SongDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Shanshan ZhangDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Yu QiaoDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Li CheDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.ORCID http://orcid.org/0000-0001-7971-8725
John GordanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA.
Kaiwen HuDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yan Liu307 Hospital of Academy of Military Medical Science, Beijing, China. 13911798288@163.com.
Diego F CalvisiInstitut für Pathologie, Universitätsmedizin Greifswald, Greifswald, Germany. diego.calvisi@uni-greifswald.de.
Xin ChenDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, USA. xin.chen@ucsf.edu.ORCID http://orcid.org/0000-0002-9588-0164
University of California, San Francisco · USBeijing University of Chinese Medicine · CNAcademy of Military Medical Sciences · CNUniversitätsmedizin Greifswald · DE

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Molecular Genetics of Liver CancersR01CA136606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2009 to 2016
$2.6M
Signaling cascades in cholangiocarcinoma developmentR01CA190606 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, XIN · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA136606NCI NIH HHS R01 CA190606NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Liver cancer comprises a group of malignant tumors, among which hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common. ICC is especially pernicious and associated with poor clinical outcome. Studies have shown that a subset of human ICCs may originate from mature hepatocytes. However, the mechanisms driving the trans-differentiation of hepatocytes into malignant cholangiocytes remain poorly defined. We adopted lineage tracing techniques and an established murine hepatocyte-derived ICC model by hydrodynamic injection of activated forms of AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes. Wild-type, Notch1

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBile Duct NeoplasmsBile Ducts, IntrahepaticCarcinoma, HepatocellularCell Cycle ProteinsCell Line, TumorCholangiocarcinomaFemaleHepatocytesLiver NeoplasmsMaleMice, TransgenicPhosphoproteinsProto-Oncogene Proteins c-aktReceptor, Notch1Adaptor Proteins, Signal TransducingCell Cycle ProteinsNotch1 protein, mouseNotch2 protein, mousePhosphoproteinsProto-Oncogene Proteins c-aktReceptor, Notch1Receptor, Notch2Yap1 protein, mouseYAP-Signaling Proteins

Identifiers

PMID29545603
PMCPMC6002343
OpenAlexW2767231608

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.